Certara, Inc. (NASDAQ:CERT) Shares Sold by 2Xideas AG

2Xideas AG trimmed its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 62.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 206,014 shares of the company’s stock after selling 349,499 shares during the period. 2Xideas AG owned about 0.13% of Certara worth $2,194,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CERT. Venturi Wealth Management LLC grew its stake in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the period. Blue Trust Inc. increased its position in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after purchasing an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its stake in shares of Certara by 204.7% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after acquiring an additional 3,656 shares during the period. Finally, KBC Group NV raised its position in Certara by 64.1% in the fourth quarter. KBC Group NV now owns 7,998 shares of the company’s stock valued at $85,000 after purchasing an additional 3,125 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Trading Down 2.4 %

NASDAQ:CERT opened at $9.55 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a 12-month low of $9.21 and a 12-month high of $19.18. The business has a 50 day simple moving average of $12.14 and a 200 day simple moving average of $11.41. The firm has a market capitalization of $1.54 billion, a P/E ratio of -47.75, a P/E/G ratio of 9.29 and a beta of 1.64.

Analysts Set New Price Targets

Several research firms recently issued reports on CERT. William Blair reaffirmed a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Barclays upped their price target on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. Finally, TD Cowen initiated coverage on shares of Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Certara has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.